CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 121 enrolled
Drug / intervention
Cetuximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01827956
NCT01827956N/ACompleted
CompareCT.gov

Role of FCγRIIIA and FCγRIIA Receptor Polymorphisms in Cetuximab Activity Used in Palliative Treatment of Upper Aerodigestive Tract Tumours

Institut Bergonié·observational·Posted Apr 10, 2013·Updated Dec 29, 2025

In Brief

An observational study evaluating Cetuximab for Upper Gingival Squamous Cell Carcinoma. Completed, enrolled 121 participants across 1 site.

Detailed Summary

Hypothesis: Cetuximab, an anti-EGFR antibody, is used with radiotherapy in the treatment of locally advanced and inoperable upper aerodigestive tract cancers. Actually, no predictive biomarkers of Cetuximab antitumor activity are known in this setting. It has been shown recently that FCγRIIIA and FCγRIIA receptor polymorphisms played a role in antitumor activity of trastuzumab and cetuximab. The investigators therefore hypothesized that FCγRIIIA and FCγRIIA receptor polymorphisms may play a predictive role in Cetuximab effectiveness in upper aerodigestive tract cancers with recurrence or metastatic disease that make them inaccessible to loco regional treatment.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUpper Gingival Squamous Cell Carcinoma
CountriesFrance
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 10, 2013
Enrollment StartAug 1, 2009
Primary CompletionAug 1, 2011
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 13.2 years ago

Interventions

Cetuximabdrug

Blood sample for identifying the polymorphism of FCGR3A and FCGR2A genes